Lantheus (NASDAQ:LNTH) Stock Price Up 5.1% - Should You Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report)'s stock price rose 5.1% on Monday . The company traded as high as $114.26 and last traded at $113.49. Approximately 195,166 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 949,610 shares. The stock had previously closed at $107.98.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target on the stock. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. Finally, Truist Financial lowered their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Stock Up 6.9 %

The company has a market capitalization of $8.02 billion, a P/E ratio of 18.91 and a beta of 0.51. The firm's 50 day moving average price is $108.13 and its two-hundred day moving average price is $94.87. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Insider Transactions at Lantheus

In other news, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company's stock, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Lantheus

Several large investors have recently made changes to their positions in the stock. Chartwell Investment Partners LLC boosted its holdings in shares of Lantheus by 58.8% in the 3rd quarter. Chartwell Investment Partners LLC now owns 35,800 shares of the medical equipment provider's stock valued at $3,929,000 after buying an additional 13,257 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Lantheus by 11.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,935 shares of the medical equipment provider's stock valued at $542,000 after purchasing an additional 510 shares during the last quarter. Atria Investments Inc acquired a new stake in Lantheus during the 3rd quarter valued at $330,000. Assetmark Inc. lifted its holdings in Lantheus by 11.4% during the 3rd quarter. Assetmark Inc. now owns 62,802 shares of the medical equipment provider's stock valued at $6,893,000 after purchasing an additional 6,442 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in Lantheus during the 3rd quarter valued at $988,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.